Alembic Pharmaceuticals has announced the appointment of Rajkumar Baheti as a Non-Executive Non-Independent Director, effective April 1, 2026. The appointment, based on the Nomination and Remuneration Committee’s recommendation, is subject to member approval via postal ballot. The board also approved the Unaudited Financial Results for Q3 2026, with revenue from operations at ₹1,692.74 crore.
Leadership Change
Alembic Pharmaceuticals’ Board of Directors has appointed Rajkumar Baheti as a Non-Executive Non-Independent Director. This decision was made based on the recommendation of the Nomination and Remuneration Committee. The appointment is set to take effect on April 1, 2026, following the completion of his tenure as an Executive Director on March 31, 2026. The appointment is subject to the approval of the members through a postal ballot.
Financial Performance: Q3 2026
The board approved the Unaudited Financial Results for the quarter and nine months ending December 31, 2025. Key highlights include:
- Revenue from Operations: ₹1,692.74 crore for Q3 2026 and ₹5,497.18 crore for the nine-month period.
- Total Income: ₹1,891.81 crore for Q3 2026 and ₹5,526.09 crore for the nine-month period.
- Profit before Tax: ₹161.50 crore for Q3 2026 and ₹575.32 crore for the nine-month period.
- Total Comprehensive Income: ₹139.90 crore for Q3 2026 and ₹482.61 crore for the nine-month period.
Earnings per share for Q3 2026 stood at ₹6.76, while for the nine months, it was ₹24.02.
Director’s Profile
Rajkumar Baheti, the newly appointed director, is a Commerce graduate and a fellow member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India. He brings 44 years of extensive professional experience in finance, including corporate finance, financial governance, and regulatory compliance. He has also held senior leadership roles in reputed organizations.
Source: BSE
